Recent News

Fixed-Dose Pertuzumab-Based Regimen Under Study in FeDeriCa Trial

Could Regularly Drinking Sugar-Sweetened Soda Be Linked to Breast Cancer Mortality?

Is Surveillance Mammography Necessary in Older Breast Cancer Survivors?

AACR 2021: Neratinib Plus Fulvestrant for HER2-Mutant Metastatic Breast Cancer

FDA Brief: Cryoablation Technology Receives Breakthrough Device Designation in Breast Cancer

Are Type 2 Diabetes and Metformin Use Associated With Breast Cancer Risk?

Sacituzumab Govitecan-hziy Receives Regular FDA Approval for Triple-Negative Breast Cancer

FDA Grants Two New Breakthrough Device Designations for MRD Testing

Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel

KEYNOTE-355 Update on Pembrolizumab in Triple-Negative Breast Cancer

Risk of Breast Cancer in Common Drugs for Diabetes and Obesity

Endocrine Therapy for Men With Breast Cancer: Estradiol Levels, Sexual Function, and Quality of Life

Company Announces Discontinuation of Development of Oral Taxane Tesetaxel

Miami Breast Cancer Conference 2021: DESTINY-Breast01 Trial Update on Trastuzumab Deruxtecan-nxki

Miami Breast Cancer Conference 2021: Neratinib-Based Regimens for CNS Metastases

Are Most Women Who Forgo Reconstruction After Mastectomy Satisfied With the Results?

Miami Breast Cancer Conference 2021: Tolerability of Capecitabine in U.S. Patients With Triple-Negative Breast Cancer

Miami Breast Cancer Conference 2021: Comparing Radiolabeled Mapping Agents in Identifying Sentinel Lymph Nodes

Margetuximab-cmkb Versus Trastuzumab in ERBB2-Positive Advanced Breast Cancer

Miami Breast Cancer Conference 2021: Neoadjuvant Chemotherapy in Minority Groups

PD-L1 mRNA Expression and Treatment Response in Triple-Negative Breast Cancer

FDA Flags Safety Concerns for Oral Paclitaxel Plus Encequidar in Treatment of Breast Cancer

ASCO Guideline: Focus on Optimal Neoadjuvant Therapy for Breast Cancer

Can Androgen Receptor Agonists Improve Outcomes in Estrogen Receptor–Positive Breast Cancer?

Neoadjuvant Regimens Compared in Advanced Operable Breast Cancer

COVID-19 and Breast Cancer: Protective Role for Antiestrogen Therapies?

MONALEESA-7 Update: Ribociclib Plus Endocrine Therapy for Advanced Breast Cancer

Phase II Basket Trial of Dual HER2-Targeted Therapy in Metastatic Breast Cancer

World Health Organization Reports Breast Cancer Now the Most Common Type of Cancer Worldwide

Ribociclib/Letrozole in UK Subgroup of Phase IIIb Trial of Advanced Breast Cancer

Survival Outcomes in Early HER2-Positive Breast Cancer: Focus on Body Mass Index

Outcomes With Chemotherapy May Differ by Menopausal Status: Report From RxPONDER

Addition of Entinostat to Endocrine Therapy for Advanced Breast Cancer

Are Statins Cardioprotective in Patients Treated With Chemotherapy for Early Breast Cancer?

Adding a Tumor Bed Boost to Whole-Breast Irradiation for Ductal Carcinoma in Situ

Androgen Receptor Modulator in ER-Positive/AR-Positive Breast Cancer

Are Individuals With Multiple Sclerosis at Higher Risk of Developing Breast Cancer?

IPATunity130 Trial of Ipatasertib Plus Paclitaxel for Advanced Triple-Negative Breast Cancer

Oral Contraceptives and Risk of Breast Cancer

Tesetaxel Plus Reduced-Dose Capecitabine in Metastatic Breast Cancer

FDA Brief: Zenocutuzumab Granted Fast Track Designation for NRG1 Fusion Cancers

Shortened Course of Radiotherapy for Breast Cancer After Surgery

Enumeration of CTCs in Predicting Therapeutic Outcomes in Metastatic Breast Cancer

Preclinical Trial Explores Anti–PD-1 Strategies for Triple-Negative Breast Cancer

Recognizing Adverse Symptoms in Patients Undergoing Breast Radiotherapy

Trop-2 Expression and Sacituzumab Govitecan in Triple-Negative Breast Cancer

SABCS 2020: Pembrolizumab Plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

Comparison of Number of Fractions of Accelerated Partial Breast Irradiation

Margetuximab-cmkb in Combination With Chemotherapy Approved by FDA for Metastatic Breast Cancer

SABCS 2020: Patient-Reported Outcomes With Atezolizumab Plus Chemotherapy in Triple-Negative Breast Cancer

Patient-Reported Outcomes After Switch to Endocrine Therapy in Metastatic Breast Cancer

SABCS 2020: Provider Survey on Managing Early-Stage Breast Cancer Amid COVID-19

SABCS 2020: Initial PENELOPE-B Results With Palbociclib-Based Therapy for Primary Breast Cancer

SABCS 2020: Does Breast Cancer Influence Mortality From COVID-19?

Is Increased Adiposity Causally Protective for Breast Cancer?

ESMO Asia 2020: MONARCH 2 Update on Abemaciclib Plus Fulvestrant in East Asian Patients With Breast Cancer

De-escalated Weekly Dose of Palliative Breast Radiotherapy

Final Overall Survival Results From nextMONARCH Trial in Metastatic Breast Cancer

ESMO Asia 2020: Subgroup Analysis of KEYNOTE-522 Supports Use of Pembrolizumab in Triple-Negative Breast Cancer

SITC 2020: Cyclophosphamide Prior to Pembrolizumab in Metastatic Triple-Negative Breast Cancer

ASTRO 2020: Risk of Radiation-Induced Heart Disease in Patients Treated for Breast Cancer

Novel CDK4/6 Inhibitor Plus Fulvestrant Under Study in Advanced Breast Cancer

Pembrolizumab Plus Chemotherapy Receives Accelerated Approval in Triple-Negative Breast Cancer

Early Breast Cancer: Risk-Adapted Targeted Intraoperative Radiotherapy During Lumpectomy

ASTRO 2020: Olaparib Plus Radiotherapy for Advanced Triple-Negative Breast Cancer

Risk of Breast Cancer and Frequency of Pathogenic Variants in Older Women

ASTRO 2020: Initial 2-Year Results of Comparison of Breast Irradiation Therapies

Study Finds Potential Therapeutic Benefit of Honeybee Venom in Breast Cancer Cells

Reduced Dose of Eribulin in Elderly Patients With Advanced Breast Cancer